CDY 19.2% 31.0¢ cellmid limited

News: Cellmid targets substantial sales growth in 2015

  1. A larger product range, increases to its pharmacy distribution and larger salon sales force are expected to deliver substantial sales growth for its consumer health business in 2015. The company is also progressing its lead humanised oncology anti-midkine antibody (CAB102) for use in solid tumours towards the next value inflection point.

 
watchlist Created with Sketch. Add CDY (ASX) to my watchlist
(20min delay)
Last
31.0¢
Change
0.05(19.2%)
Mkt cap $26.07M
Open High Low Value Volume
29.0¢ 31.0¢ 29.0¢ $24.15K 78.88K

Buyers (Bids)

No. Vol. Price($)
1 1786 28.0¢
 

Sellers (Offers)

Price($) Vol. No.
31.5¢ 45000 1
Last update - 16.10pm 12/12/2018 (20 minute delay) ?
(live)
Last
31.0¢
  Change
0.05 ( 21.6 %)
Open High   Low Volume
31.0¢ 31.0¢   31.0¢ 12721
Last updated 10.48am 12/12/2018 (live) ?
CDY (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.